COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Use of Laser-Assisted Indocyanine Green Dye Angiography to Predict Mastectomy Skin Flap Viability (ICG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01554267
Recruitment Status : Unknown
Verified May 2014 by Duc T Bui, MD, Stony Brook University.
Recruitment status was:  Recruiting
First Posted : March 14, 2012
Last Update Posted : May 13, 2014
Information provided by (Responsible Party):
Duc T Bui, MD, Stony Brook University

Brief Summary:

In the investigators previous study of 51 breast reconstructions (32 patients), we compared three different assessments of vascular perfusion of tissue; clinical judgment, fluorescein dye angiography (FDA) and laser-assisted indocyanine green dye angiography (ICG). Because tissue with poor perfusion becomes necrotic and can compromise the success of breast reconstruction, it is important that tissue with poor perfusion be removed at the time of the reconstructive surgery. However, it is also important to remove the least amount of potentially necrotic tissue as possible so that the breast reconstruction is not compromised by lack of skin. Therefore finding the best way to assess potentially necrotic tissue is a vital clinical question. In the initial study the 3 different assessment methods which were made at the time of surgery were compared to the subsequent development of necrotic tissue.

In the initial study, clinical judgment was the basis for determining the tissue removed because it had the potential to become necrotic. The investigators collected data with the FDA system and ICG system, but this data was not used in making the clinical decisions. The study followed the progression of tissue to overt necrosis and this clinical outcome was then compared to the predictions made by the three different assessment strategies. The investigators found that clinical judgment failed to detect tissue which subsequently became necrotic in 21 out of 51 instances for a failure rate of 41%. The FDA system predicted larger areas of potentially necrotic tissue than clinical judgment, but was found to over-predict the area that became necrotic by 82% - 88% (88% if all cases were included and 82% if only those cases which subsequently developed necrosis were included). Although the ICG system is similar to the FDA system in that a dye is used to assess perfusion, the ICG system has enhanced software which improves the estimated perfusion. The ICG system provided 90% sensitivity and 100% specificity in the predicted vs. actual necrotic tissue at specific absolute perfusion units values.

Hypothesis: Using the values of absolute perfusion units discovered in the previous study and implementing its use in the operating room will decrease all-inclusive necrosis rates to below 10%, reflecting a 31% decrease in the investigators necrosis rate.

Condition or disease Intervention/treatment Phase
Breast Cancer Breast Reconstruction Mastectomy Device: Laser-Assisted ICG Dye Angiography (SPY System) Not Applicable

Detailed Description:
The investigators current rate of the development of all-inclusive mastectomy skin necrosis was approximately 41%. This means that current methods of clinical assessment fail to identify regions of mastectomy skin with poor blood flow that lead to necrosis in 41% of patients. The investigators know that using the SPY imaging system is more sensitive for necrosis than clinical assessment. With SPY Q analysis the investigators hope to obtain 90% sensitivity, 100% specificity at absolute perfusion unit values identified in the previous study. The investigators do not anticipate obtaining a 0% all-inclusive necrosis rate but do believe they can eliminate all clinically significant necrosis that would result in operative debridement or removal of implant. The less severe forms of necrosis including epidermolysis and incisional necrosis are self-limiting and usually do not require invasive interventions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: The Use of Laser-Assisted Indocyanine Green Dye Angiography to Predict Intraoperative Mastectomy Skin Flap Viability During Breast Reconstruction
Study Start Date : January 2014
Estimated Primary Completion Date : January 2015
Estimated Study Completion Date : May 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Mastectomy Skin Flap SPY Excision
Single arm study where areas of necrosis predicted by Laser-Assisted Indocyanine Green Dye Angiography (SPY system) will be excised intraoperatively during breast reconstruction surgery.
Device: Laser-Assisted ICG Dye Angiography (SPY System)
7.5-10mg of ICG dye will be injected at 2 different time points during breast reconstruction with the assistance of the SPY system to determine areas of skin with poor blood flow. These areas are excised during the operation in order to decrease postoperative complications including mastectomy skin flap necrosis and reconstruction failure.
Other Names:
  • Lifecell SPY System
  • Novadaq SPY System

Primary Outcome Measures :
  1. Mastectomy Skin Flap Necrosis [ Time Frame: 30 days postop ]
    All-inclusive mastectomy skin flap necrosis including: epidermolysis, partial/superficial necrosis, and full-thickness necrosis.

Secondary Outcome Measures :
  1. Infection [ Time Frame: 30 days postop ]
    Superficial, Deep or Organ space surgical site infection as defined by the CDC. Patients treated with oral or IV antibiotics will be documented, including patients who have loss of implant due to infection.

  2. Wound Dehiscence or Implant Extrusion [ Time Frame: 30 days postop ]
    Wound breakdown and exposure of acellular dermal matrix and implant will be documented.

  3. Seroma/Hematoma [ Time Frame: 30 days postop ]
    Any evidence of seroma/hematoma will be documented and be documented based on requirement of a surgical intervention or observation.

  4. Removal or Loss of Implant [ Time Frame: 30 days postop ]
    Patients who require removal of their implants will be documented along with the primary cause of their loss of implant.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Being scheduled for unilateral or bilateral mastectomy (prophylactic or for the treatment of cancer) followed by breast construction using a Tissue Expander
  2. Consent to participation in the study.

Exclusion Criteria:

  1. Refusal to consent to participation in the study
  2. Inability to tolerate the administration of indocyanine green dye due to iodine allergy
  3. A positive pregnancy test during preoperative evaluation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01554267

Layout table for location contacts
Contact: Brett T Phillips, MD 631-444-8020
Contact: Sami U Khan, MD 631-444-9394

Layout table for location information
United States, New York
Stony Brook University Recruiting
Stony Brook, New York, United States, 11794
Sponsors and Collaborators
Stony Brook University
Layout table for investigator information
Principal Investigator: Duc T Bui, MD Stony Brook University
Study Director: Brett T Phillips, MD Stony Brook University
Layout table for additonal information
Responsible Party: Duc T Bui, MD, Associate Professor of Surgery, Stony Brook University Identifier: NCT01554267    
Other Study ID Numbers: 127891
First Posted: March 14, 2012    Key Record Dates
Last Update Posted: May 13, 2014
Last Verified: May 2014
Keywords provided by Duc T Bui, MD, Stony Brook University:
Mastectomy skin flap necrosis
Breast reconstruction
Indocyanine Green Dye